For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Some companies are keeping remote work policies even as other firms call people back to the office. Companies like Atlassian, Dropbox, and Deel report increased job applicants and retention rates.

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Horrifying footage has captured the moment a six-meter python dragged a tour guide underwater, just moments before coiling around his neck. Experienced snake catcher, Heru, was traveling down a river ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Forbes contributors publish independent expert analyses and insights. Bryan Penprase covers global innovations in higher education and STEM The College of the Ozarks campus is seen on March 17, 2003, ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The Python Software Foundation (PSF) has withdrawn its $1.5 million grant proposal to the U.S. National Science Foundation (NSF) due to funding terms forcing a compromise on its commitment to ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...